Investigating how TREK-1 potassium channels can protect lungs from damage caused by too much oxygen.
Trek-1 Potassium Channels Protect from Hyperoxia-induced Acute Lung Injury
This study is looking at how too much oxygen can harm the lungs of people who need oxygen therapy, and it aims to find new ways to protect their lungs by focusing on specific channels in lung cells that may help reduce damage and inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10792593 on NIH RePORTER |
What this research studies
This research focuses on understanding how excessive oxygen exposure can lead to acute lung injury, particularly in patients receiving oxygen therapy for respiratory failure. The study aims to identify the role of TREK-1 potassium channels in lung cells and how their downregulation during hyperoxia contributes to inflammation and cell damage. By exploring these mechanisms, the research seeks to develop new therapeutic strategies to prevent lung injury and improve patient outcomes. Patients may benefit from potential new treatments that target these channels to protect their lungs during oxygen therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who require oxygen therapy for acute respiratory failure.
Not a fit: Patients who do not require oxygen therapy or have pre-existing severe lung conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent lung injury in patients receiving oxygen treatment.
How similar studies have performed: While the approach of targeting TREK-1 channels is novel, previous research has shown success in identifying molecular targets for lung injury prevention.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Schwingshackl, Andreas — University of California Los Angeles
- Study coordinator: Schwingshackl, Andreas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.